

PATIENT INFORMATION

"Your partner in patient care"

Date Needed By ______ Ship to: Patient Office Other: __

260 Broadway Brooklyn, NY 11211 Phone: 718-782-0101 Fax: 718-782-2626 www.EchoDrugs.net

DERMATOLOGY

PRESCRIBER INFORMATION

REFERRAL FORM

Fax prescription to: 718-782-2626

Faxed prescriptions can only be accepted from prescribing practitioners

| | | | NPI | State Lice | ense# | |
|---|---|--|------------------|---|--|--------------|
| Address | | | Group/Hospital _ | | | |
| City Zip | | Group/1103pital | | | | |
| Phone SS# | ± D0 | B | Address | | | |
| □Male □Female Height | _ Weight Age | | City, State, Zip | | | |
| Allergies | | DKDA | Main Phone | | Fax | |
| INSURANCE INFORMATION | | | | | | |
| Please attach front and back of all insu | rance and prescription dr | ug cards | Contact Person _ | | Phone | |
| CLINICAL EVALUATION | | | | | | |
| DIAGNOSIS | PREVIOUS TREATMEN | | | INDICATE AFFECTED AREAS | | |
| L40.9 Psoriasis L40.52 Psoriatic Arthritis L73.2 Hidradenitis Suppurativa L20.9 Atopic Dermatitis Other Diagnosis Date | Medication Reason fo Biologics Methotrexate Oral Meds (other) PUVA UVB | | iscontinuation | FRONT BACK | | |
| Years with disease | □ Topicals | | | | | |
| Psoriasis Type: □ Moderate □ Severe | □ Other | | | | | |
| Psoriasis Type. | Has patient been diagnosed Has patient been diagnosed Does patient have serious Is patient at risk for Hepatient Has patient have latex all Does patient have latex all | MEDICAL ASSESSMENT Has patient been diagnosed with heart failure? | | R L L L R Weight Height BSA% affected by Psoriasis Comments | | |
| | is patient platelet count g | reater than 52,000 cells | rul? Lives Lino | | | |
| PRESCRIPTION INFORMATION MEDICATION | | DOSAGE & C | IDECTIONS | | QUANTITY/DURATION | REFILLS |
| □ CIMZIA (certolizumab pegol) □ 400mg x 3 Starter Kit □ 400mg pen (200mg x 2) | DOSAGE & DIRECTIONS ☐ Psoriasis/Psoriatic Arthritis loading dose: 400mg week 0, 2, 4 ☐ Psoriasis/Psoriatic Arthritis maintenance dose: 400mg every 4 weeks | | | QUANTITY/DURATION | REFILLS | |
| □ COSENTYX (secukinumab) □ 150mg syringe □ 150mg pen | □ Psoriatic arthritis induction (optional): 150mg subcutaneously at weeks 0, 1, 2, 3, and 4 □ Psoriatic arthritis maintenance: 150mg subcutaneously every 4 weeks □ Plaque Psoriasis induction: 300mg subcutaneously at weeks 0, 1, 2, 3, and 4 □ Plaque Psoriasis maintenance: 300mg subcutaneously every 4 weeks | | | | | |
| □ DUPIXENT (dupilumab) □ 300mg/2ml prefilled syringe □ 300mg/2ml pen | □ Atopic Dermatitis induction: Inject 600mg subcutaneously in 2 different injection sites □ Atopic Dermatitis maintenance: Inject 300mg subcutaneously every other week | | | | | |
| □ ENBREL (etanercept) □ 50mg SureClick □ 300mg/2ml prefilled syringe | □ Psoriasis loading dose: 50mg subcutaneously TWICE weekly for 3 months □ Psoriasis/Psoriatic Arthritis maintenance dose: 50mg subcutaneously EACH week | | | | | |
| \square HUMIKA (adalimumab) \square 40ma/0 4ml pen \square 40ma/0 4ml syringe | □ Psoriasis starter: 80mg day 1, 40mg day 8, 40mg every 2 weeks □ Psoriasis maintenance: 40mg subcutaneously every 2 weeks □ HS starter: 160mg day 1, 80mg day 15, 40mg EACH week starting day 29 □ HS maintenance: 40mg subcutaneously EACH week | | | | | |
| □ ILUMYA (tildrakizumab-asmn)□ 100mg syringe | □ Psoriasis: 100mg at weeks 0, 4, then ONCE every 12 weeks | | | | | |
| □ OTEZLA (apremilast) □ Otezla Starter Pack □ 30mg tab | □ Psoriasis/Psoriatic Arthritis starter dose: titration directions on pack □ Psoriasis/Psoriatic Arthritis maintenance dose: 30mg TWICE a day | | | | | |
| □ SKYRIZI (risankizumab-rzaa)□ 150mg (2x75mg syringe) | □ Psoriasis: 150mg at weeks 0, 4, then ONCE every 12 weeks | | | | | |
| □ STELARA (ustekinumab)□ 45mg□ 90mg | ☐ Plaque Psoriasis/Psoriatic Arthritis (<100kg): 45mg subcutaneously at weeks 0, 4, then every 12 weeks ☐ Plaque Psoriasis/Psoriatic Arthritis (>100kg): 90mg subcutaneously at weeks 0, 4, then every 12 weeks | | | | | |
| □ TREMFYA (guselkumab) □ 100mg pen □ 100mg syringe | □ Plaque Psoriasis/Psoriatic Arthritis: 100mg subcutaneously at weeks 0, 4, then every 8 weeks | | | | | |
| □ XELJANZ (tofacitinib citrate) □ 11mg XR tab □ 5mg tab | □ Psoriatic Arthritis: 5mg TWICE daily □ Psoriatic Arthritis: 11mg ONCE daily | | | | | |
| □ OTHER: | □ Directions: | | | | | |
| By signing this form and utilizing our services, you are authorizing to serve as your prior authorization designated agent in dealing of the serve as your prior authorization designated agent in dealing of the services. This fax is intended to be delivered only to the results of the services of the services of the services. | with medical and prescription insurant amed addressee. It contains material to | nce companies. Pres that is confidential, privile | | | DAW Datee not the named addresses you should not | disseminate, |
| distribute or copy this fax. Please notify the sender immediately if you | | _ | | | | |